Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled PC786 versus placebo in an RSV human challenge study
2017-002563-18Phase 2Completed
- Sponsor
- Pulmocide
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing PC786 with Placebo (2 arms). Primary endpoint: RSV viral load AUC. Started Jul 2017; status: completed.
02
Drugs
PC786
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2017-002563-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002563-18.